Nontoxic Goiter Follow-up
- Author: Stephanie L Lee, MD, PhD; Chief Editor: George T Griffing, MD more...
Further Outpatient Care
- The patient with a large goiter and no obstructive symptoms can be monitored in an outpatient setting. Conduct a physical examination every 6 months to determine if obstructive symptoms have developed or worsened and to perform thyroid function tests (ie, TSH, free T4).
- Depending on iodine intake in the diet, some of these patients develop thyroid autonomy and thyrotoxicosis.
- Often, thyroid imaging is not necessary when the patient is examined by an endocrinologist experienced in thyroid examinations. The method of choice is ultrasonography unless the goiter extends into the thoracic inlet.
- Routine nuclear scintigraphy is not necessary.
Transfer
- Transfer may be required in patients with significant tracheomalacia who require surgery. Long-term compression of the trachea by a nontoxic goiter causes tracheal cartilage to lose its strength. This can be life threatening, and tracheal intubation or tracheotomy may be required.
- Additionally, if a goiter extends significantly into the thorax, a thoracic surgeon may be needed to open the chest wall to fully excise the goiter.
Deterrence/Prevention
- Prevention of endemic goiter may be accomplished by iodine supplementation, using iodine supplements in drinking water sources or iodized oil on bread (strategies that can be applied to a whole country).
Complications
- Complications of a nontoxic goiter occur because of growth and compression of neck structures or the development of areas of autonomy and thyrotoxicosis.[17]
Prognosis
- Prognosis is good.
- Usually, nontoxic goiters grow very slowly over many years. Any rapid growth behavior must be evaluated for either degeneration or hemorrhage of a nodule or for growth of a neoplasm.
- Often, in patients who present with progressive goiter growth, those with significant dysphagia or dyspnea must be evaluated for subtotal thyroidectomy.
- In some patients, radioactive iodine therapy can be considered, especially if the patient is older.
Patient Education
- Thyroid self-examination may be taught to patients, allowing them to monitor their own body for early changes in gland size.
- For excellent patient education resources, visit eMedicine's Endocrine System Center. Also, see eMedicine's patient education article Thyroid Problems.
Bahn RS, Castro MR. Approach to the patient with nontoxic multinodular goiter. J Clin Endocrinol Metab. May 2011;96(5):1202-12. [Medline].
Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. Nov 2009;19(11):1167-214. [Medline].
Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab. Dec 2008;22(6):929-39. [Medline].
Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. Jul 2008;32(7):1313-24. [Medline].
Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf). Jun 2007;66(6):757-64. [Medline].
Baczyk M, Pisarek M, Czepczynski R, Ziemnicka K, Gryczynska M, Pietz L, et al. Therapy of large multinodular goitre using repeated doses of radioiodine. Nucl Med Commun. Mar 2009;30(3):226-31. [Medline].
Bonnema SJ, Hegedus L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes. Oct 2009;16(5):379-84. [Medline].
Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid. May 2008;18(5):509-16. [Medline].
Medeiros-Neto G, Marui S, Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine. Apr 2008;33(2):109-17. [Medline].
Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. Oct 2008;14(7):832-9. [Medline].
Fast S, Nielsen VE, Grupe P, et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. May 2009;50(5):732-7. [Medline].
Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. Jun 2011;21(6):593-646. [Medline].
Yetkin G, Uludag M, Onceken O, et al. Does unilateral lobectomy suffice to manage unilateral nontoxic goiter?. Endocr Pract. Jan-Feb 2010;16(1):36-41. [Medline].
Phitayakorn R, McHenry CR. Follow-up after surgery for benign nodular thyroid disease: evidence-based approach. World J Surg. Jul 2008;32(7):1374-84. [Medline].
Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Five-year Follow-up of a Randomized Clinical Trial of Total Thyroidectomy versus Dunhill Operation versus Bilateral Subtotal Thyroidectomy for Multinodular Nontoxic Goiter. World J Surg. Feb 20 2010;[Medline].
[Best Evidence] Worni M, Schudel HH, Seifert E, et al. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg. Dec 2008;248(6):1060-6. [Medline].
Erbil Y, Barbaros U, Temel B, et al. The impact of age, vitamin D(3) level, and incidental parathyroidectomy on postoperative hypocalcemia after total or near total thyroidectomy. Am J Surg. Apr 2009;197(4):439-46. [Medline].
Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet. Jul 28 1990;336(8709):193-7.
Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. Oct 1999;84(10):3636-41. [Medline]. [Full Text].
Braverman LE, Utiger RD, Hermus AR, Huysmans DA:. Clinical manifestations and treatment of nontoxic diffuse and nodular goiter. In: Werner & Ingbar's The Thyroid. Baltimore, Md: Lippincott Williams & Wilkins;. 2000;866-871.
Hegedus L, Gerber H. Multinodular goiter. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 2001;2:1517-1528.
Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med. May 14 1998;338(20):1438-47. [Medline].
Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab. Oct 1998;83(10):3401-8. [Medline]. [Full Text].
Huysmans D, Hermus A, Edelbroek M, et al. Radioiodine for nontoxic multinodular goiter. Thyroid. Apr 1997;7(2):235-9. [Medline].
Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med. Nov 15 1994;121(10):757-62. [Medline].
Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab. Oct 2000;85(10):3592-6. [Medline]. [Full Text].
Netterville JL, Coleman SC, Smith JC, et al. Management of substernal goiter. Laryngoscope. Nov 1998;108(11 Pt 1):1611-7. [Medline].
Perrild H, Hansen JM, Hegedus L. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol (Copenh). Jul 1982;100(3):382-7. [Medline].
Rios A, Rodriguez JM, Canteras M, et al. Surgical management of multinodular goiter with compression symptoms. Arch Surg. Jan 2005;140(1):49-53. [Medline]. [Full Text].
Ross DS. Thyroid hormone suppressive therapy of sporadic nontoxic goiter. Thyroid. Fall 1992;2(3):263-9. [Medline].

